First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).

被引：36
|
作者：
Alsina, Maria
Boni, Valentina
Schellens, Jan H. M.
Moreno, Victor
Bol, Kees
Westendorp, Martine
Sirulnik, L. Andres
Tabernero, Josep
Calvo, Emiliano
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] START Madrid CIOCC, Hosp HM Univ Sanchinarro, Madrid, Spain
[3] Netherlands Canc Inst, Amsterdam, Netherlands
[4] Start Madrid FJD, Hosp Fdn, Madrid, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Vall Hebron Univ Hosp, Inst Oncol VHIO, Barcelona, Spain
[7] START Madrid, Centro Integral Oncol Clara Campal, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2522
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Richards, D.
    Braiteh, F.
    Anthony, S.
    Edenfield, W.
    Hellerstedt, B.
    Raju, R.
    Conkling, P.
    McDonagh, C.
    Frye, S.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 170 - 170
  • [22] HER1, HER2, HER3 and HER4-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer
    Bachmann, C.
    Brockhoff, G.
    Grischke, E.
    Staebler, A.
    Schittenhelm, J.
    Wallwiener, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 17 - 17
  • [23] Optimizing outcomes in patients (pts) with HER2+metastatic breast cancer (MBC) through continuous inhibition of HER2 activity: A single institution study
    Fedele, P.
    Orlando, L.
    Schiavone, P.
    Calvani, N.
    Marino, A.
    Nacci, A.
    Sponziello, F.
    Mazzoni, E.
    Rizzo, P.
    Cinieri, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Saeki, Toshiaki
    Mukai, Hirofumi
    Aogi, Kenjiro
    Shigekawa, Takashi
    Ueda, Shigeto
    Naito, Yoichi
    Matsubara, Nobuaki
    Takashima, Seiki
    Hara, Fumikata
    Yamashita, Tomonari
    Ohwada, Shoichi
    Sasaki, Yasutsuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+metastatic breast cancer (MBC)
    Hamilton, Erika Paige
    Yardley, Denise A.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Borges, Virginia F.
    Moulder, Stacy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and/or trastuzumab, in HER2+metastatic breast cancer (MBC)
    Hamilton, Erika
    Yardley, Denise A.
    Hortobagyi, Gabriel
    Walker, Luke
    Borges, Virginia F.
    Moulder, Stacy
    CANCER RESEARCH, 2015, 75
  • [27] Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer
    Gandhi, Shipra
    Forsyth, Peter A. J.
    Opyrchal, Mateusz
    Ahmed, Kamran A.
    Attwood, Kristopher
    Levine, Ellis Glenn
    O'Connor, Tracey L.
    Early, Amy P.
    Fenstermaker, Robert Alan
    Prasad, Dheerendra
    Takabe, Kazuaki
    Czerniecki, Brian J.
    Kalinski, Pawel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+metastatic breast cancer (MBC): phase I and phase II trial results
    Burris, H., III
    Vukelja, S.
    Krop, I.
    Modi, S.
    Klencke, B.
    Girish, S.
    Sliwkowski, M. X.
    Dresser, M.
    Phillips, G. L.
    Rugo, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 267
  • [29] Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
    Andrea Sassen
    Justine Rochon
    Peter Wild
    Arndt Hartmann
    Ferdinand Hofstaedter
    Stephan Schwarz
    Gero Brockhoff
    Breast Cancer Research, 10
  • [30] Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
    Sassen, Andrea
    Rochon, Justine
    Wild, Peter
    Hartmann, Arndt
    Hofstaedter, Ferdinand
    Schwarz, Stephan
    Brockhoff, Gero
    BREAST CANCER RESEARCH, 2008, 10 (01):
12345